Impact of all oral anti-hepatitis C virus therapy: A meta-analysis

doi:10.4254/wjh.v7.i5.806

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7368)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

513

WORD

221

HTML

3808

Figures (1-1)

179

Tables (1-3)

166

Sum=4887

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1052

Download

1429

Sum=2481

Apr 18, 2015 (publication date) through Jul 2, 2024

Times Cited of This Article

Times Cited (46)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Apr 18, 2015; 7(5): 806-813
Published online Apr 18, 2015. doi: 10.4254/wjh.v7.i5.806

Table 3 Various direct acting antivirals: Approved and investigational

Currently FDA approved DAA	Under development butcurrently non-FDA approved
TEL	Daclatasvir,
BOC	Asunaprevir,
LED	Beclabuvir
SOF	Faldaprevir
SIM	Mericitabine
SOF/LED (Harvoni)	Tegobuvir
Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir (Viekira Pak)¹	Grazoprevir with Elbasvir

¹FDA has approved Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir (Viekira Pak) on December 19, 2014, i.e., after submission of our manuscript and is not included in our analysis. FDA: Food and Drug Administration; TEL: Telaprevir; BOC: Boceprevir; SOF: Sofosbuvir; SIM: Simeprevir; LED: Ledipasvir.

Citation: Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol 2015; 7(5): 806-813
URL: https://www.wjgnet.com/1948-5182/full/v7/i5/806.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i5.806